Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

Leukemia. 2021 Nov;35(11):3314-3318. doi: 10.1038/s41375-021-01210-8. Epub 2021 Mar 17.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm*
  • Follow-Up Studies
  • Humans
  • Imidazoles / therapeutic use*
  • Leukemia, Hairy Cell / drug therapy*
  • Leukemia, Hairy Cell / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Oximes / therapeutic use*
  • Pilot Projects
  • Prognosis
  • Prospective Studies
  • Salvage Therapy*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Oximes
  • dabrafenib